Arkolith/Insider Trading/ZYNE/Form 4

Stephenson Pamela

DirectorZynerba Pharmaceuticals, Inc. (ZYNE) · full profile →Form 4 · filed Jun 15, 2023
Net Selling
Open-Market Buys
$0
Open-Market Sells
$40
Net Open-Market Flow
-$40
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 14, 2023Sell(S)115$0.35$4076K
Jun 13, 2023Grant(A)48K—$076K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 13, 2023Grant(A)72K—$072K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001062993-23-013668) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML